MiR-520a-3p inhibits malignant progression of epithelial ovarian cancer by targeting SUV39H1 expression.

Human Cell
Jingwei LiJunhong Zhao

Abstract

Downregulation of microRNA-520a-3p (miR-520a-3p) has been demonstrated in several cancers, and miR-520a-3p has been shown to inhibit tumor progression, indicating its potential role as a tumor suppressor. In this study, we found that miR-520a-3p was also downregulated in epithelial ovarian cancer (EOC) tissues and cell lines. Functional assays showed that ectopic expression of miR-520a-3p suppressed EOC cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) and induced cell cycle arrest in vitro. Similarly, overexpression of miR-520a-3p inhibited tumor growth and metastasis in vivo. Mechanistically, suppressor of variegation 39H1 (SUV39H1) was identified as a novel target of miR-520a-3p through biomedical databases and dual-luciferase reporter assay. Subsequently, SUV39H1 was observed to be negatively regulated by miR-520a-3p at the mRNA and protein levels, and inversely correlated with miR-520a-3p expression in EOC tissues. Furthermore, overexpression of SUV39H1 reversed the suppressive effects of miR-520a-3p in EOC cells. Collectively, these results suggest that the miR-520a-3p/SUV39H1 axis may contribute to EOC cell proliferation and metastasis, revealing miR-520a-3p as a potential therapeutic target for t...Continue Reading

References

Sep 17, 2004·Nature·Victor Ambros
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Feb 28, 2008·Physiological Genomics·Chunxiang Zhang
Jan 13, 2009·Gynecologic Oncology·Kristy ShieldGregory E Rice
Feb 11, 2012·Virchows Archiv : an International Journal of Pathology·Jaime Prat
Sep 20, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Dorothy Ngo-Yin FanChun-Ming Wong
Nov 26, 2013·Methods in Molecular Biology·Kemal Uğur TüfekciSermin Genç
Oct 17, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Huicong LiJun Shi
May 29, 2018·CA: a Cancer Journal for Clinicians·Lindsey A TorreRebecca L Siegel
Aug 12, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Butian ZhangJinlan Jiang
Aug 18, 2018·Journal of Cellular and Molecular Medicine·Mingzhi CaiLisheng Cai
Sep 25, 2018·NPJ Precision Oncology·Soochi KimYong Sang Song
Dec 18, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jingwei LiHuian Feng
Feb 17, 2019·Journal of Experimental & Clinical Cancer Research : CR·Xiaolan ZhuYuefeng Li
Oct 11, 2019·Journal of Biochemistry·Jun ChenYa-Li Cao
Mar 15, 2020·Biological Research·Guizhi ZhaoYang Guo
Mar 21, 2020·Journal of Biochemistry·Jun ChenYa-Li Cao
Apr 21, 2020·Cancer Treatment Reviews·Tzu-Ting HuangJung-Min Lee

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
transfection
PCR
flow cytometry
immunoprecipitation
xenograft
RIP
pull down

Software Mentioned

GraphPad
Prism

Related Concepts